Toggle light / dark theme

Jesus Christ of sharks has risen 🙏


A rare event has taken place in the Cala Gonone Aquarium in Sardinia, Italy. A smooth-hound shark gave birth to a baby shark without any male interference in the tank she has been living in for the past ten years with only another smooth-hound female and no males, reports Agenzia Italia. This could prove to be the first and only parthenogenesis example in this specific species of shark, and hence, t he newborn female shark is named Ispera, which means Hope in Sardinian.

While other sharks and rays, including the bonnethead, the blacktip shark, and the zebra shark have previously been observed doing parthenogenesis, smooth-hound sharks, scientifically known as Mustelus mustelus, have never been, as far as scientists know. If confirmed, this event could be a scientific discovery of smooth-hounds’ using parthenogenesis.

Packing battery tech nobody uses in consumer devices and a half-horsepower motor, BlenderCap is one of the most ludicrously over-engineered products we’ve seen in a hot minute. At CES in Las Vegas, we took a closer look at talked with the team behind the product to find out more.

Let’s start with, er, why do we need a portable blender in the first place?

“We originally invented this just for personal use for making smoothies after the gym. I was going to CrossFit, and I wanted a protein shake after that. I made myself a shake, and it just got sort of melted and lumpy after you have worked out for an hour or two,” says Dakota Adams, co-founder at the company. “Then the idea came along to put a blender onto these Hydroflask-style bottles. Matthew [Moore] and I became friends and began working on how to pack that technology into a tiny little cap.”

A new drug that contains an ACE2 decoy molecule may be the way we stop COVID-19 permanently.


What’s Needed is a New Approach

A recent paper appearing in Science Advances published on December 7, 2022, describes a new approach to tackling COVID-19. A new drug in animal trials has shown effectiveness in stopping the spread of coronaviruses and all variants. It is the way this drug works that gives it a unique advantage not just to stop present Omicron and other COVID-19 versions but all future evolutions of the virus and other coronaviruses.

Why the confidence in this drug? Rather than synthesize antibodies to fight COVID-19 and create vaccines that deliver them to tag the virus (the mRNA approach), the Dana-Farber Cancer Institute has created a molecule that is an ACE2 receptor decoy.